BJCP British Journal of Clinical Pharmacology

DOI:10.1111/j.1365-2125.2008.03337.x

AUTHOR INDEX

AALYKKE, C. *see* GULMEZ, S.E.
ABADI, R.M. *see* SOMOGYI, A.A.
ABE, T., SEO, T., ISHITSU, T., NAKAGAWA, T., HORI, M. & NAKAGAWA, K. Association between *SCN1A* polymorphism and carbamazepine-resistant epilepsy: 304
ABILDSTROM, S.Z. *see* SØRENSEN, R.
ADKISON, K.K., VAIDYA, S.S., LEE, D.Y., KOO, S.H., LI, L., MEHTA, A.A., GROSS, A.S., POLLI, J.W., LOU, Y. & LEE, E.J.D. The *ABCG2* C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects: 233
AGRAWAL, N.G.B. *see* SCHWARTZ, J.I.
ALI, K.R. *see* MOHAMMED, Z.S.
ALI, R. *see* SOMOGYI, A.A.
AMIT, D. & RATABOLI, P.V. Adverse drug reaction (ADR) notification drop box: an easy way to report ADRs: 723
ANDERSEN, B.S. *see* GULMEZ, S.E.
ANDERSEN, M. *see* GULMEZ, S.E.
ANDERSEN, M. *see* KILDEMOES, H.W.
ANDRIES, A. *see* GULMEZ, S.E.
ANNAPANDIAN, V.M. *see* MATHEW, B.S.
ARAVAGIRI, M. *see* FENG, Y.
ARLET, P. *see* SAILLER, L.
ARLET-SUAU, E. *see* SAILLER, L.
ASAJIMA, H., SEKIGUCHI, Y., MATSUSHIMA, S., SAITO, N. & SAITO, T. QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman: 896
ASCHMANN, Y.Z. *see* LINK, B.
ASLANI, P. *see* DE ALMEIDA NETO, A.C.
ATTANE, C. *see* SAILLER, L.
ATTINÀ, T.M., OLIVER, J.J., MALATINO, L.S. & WEBB, D.J. Contribution of the M_3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed: 300
AVGIL, M. *see* DIAV-CITRIN, O.
BABU, K.S., GADZIK, F. & HOLGATE, S.T. Absence of respiratory effects with ivabradine in patients with asthma: 96
BACINO, L. *see* BAGNIS, A.
BADYAL, D.K. *see* GUPTA, A.
BAGNIS, A., LAI, S., IESTER, M., BACINO, L. & TRAVERSO, C.E. Spontaneous hyphaema in a patient on warfarin treatment: 414
BAHK, W.-M. *see* KIM, J.-R.
BARBARA, J.A. *see* TOCHIHARA, Y.
BARBUZZA, O. *see* VACCARO, M.
BARGIOTA, A. *see* PARKER, D.R.
BARNES, M. *see* NAIR, A.
BARTELINK, A.K.M. *see* DE WIJKERSLOOTH, L.R.H.
BATEMAN, D.N. *see* SANDILANDS, E.A.
BAUGHMAN, C., SPURLING, L. & MANGONI, A.A. Provision of warfarin education to hospital inpatients: 416
BÉGAUD, B. *see* GRÉGOIRE, F.
BEGG, E.J. *see* GARDINER, S.J.
BEIJNEN, J.H. *see* ZANDVLIET, A.S.
BENNETT, K. *see* OKECHUKWU, I.
BÉRARD, A. *see* PERREAULT, S.
BERGMAN, A.J. *see* MISTRY, G.C.
BERNASCONI, S. *see* LAPI, F.
BHARGAVA, R. *see* GUPTA, V.
BIES, R.R. *see* FENG, Y.
BILKER, W.B. *see* HENNESSY, S.
BISGAARD, H. *see* BØNNELYKKE, K.
BLAIS, L. *see* PERREAULT, S.
BLOUIN, J., DRAGOMIR, A., MORIDE, Y., STE-MARIE, L.-G., FERNANDES, J.C. & PERREAULT, S. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women: 117
BODMER, M. *see* LINK, B.
BØNNELYKKE, K., JESPERSEN, J.J. & BISGAARD, H. Early bioavailability of inhaled salbutamol reflects lung dose in children: 562
BOORSMA, M. *see* VAN DEN BRINK, K.I.M.
BOUCHE, M.-P. *see* SCHÖLLER-GYÜRE, M.
BOUVY, M.L. *see* MENCKEBERG, T.T.
BRAATVEDT, G.D. *see* PARKER, D.R.
BRACKE, M. *see* MENCKEBERG, T.T.
BRANCO, T. *see* PEREIRA, S.A.
BROWN, S. *see* PARKER, D.R.
BUCKLEY, N. *see* RINGLAND, C.
BUCKLEY, N.A. *see* EYER, P.
BULITTA, J.B. *see* LANDERSDORFER, C.B.
BURGGRAAF, J. *see* WILLEMZE, A.J.
BURNS, P. *see* NAIR, A.

CAIRNS, C. *see* HAWWA, A.F.
CAIXAS, U. *see* PEREIRA, S.A.
CALABRESE, E.J. Hormesis and medicine: 594
CAMPION, J. & WESTERN, A. Statins and joint pain: 570
CANONGE, J.-M. *see* SAILLER, L.
CATURLA, L. *see* MOLOKHIA, M.
CH. STRICKER, B.H. *see* VAN DER HOOFT, C.S.
CHANDY, S.J. *see* MATHEW, B.S.
CHANG, E. *see* ROLAN, P.
CHO, J.-Y. *see* KIM, J.-R.
CHO, J.-Y. *see* LIMK, S.
CHOPRA, S. *see* GUPTA, A.
'CHRIS' DELANEY, J.A. *see* OPATRNY, L.
CIPOLLONE, U. *see* COSTAGLIOLA, C.
CLEMENTI, M. *see* DIAV-CITRIN, O.
COHEN, A.F. Methods in clinical pharmacology – a tale of two worlds: 585
COHEN, A.F. *see* FRANSON, K.L.
COHEN, A.F. *see* VAN BRONSWIJK, P.
COHEN, A.F. *see* ZOETHOUT, R.W.M.
COLEMAN, J.J. Computerised Pill Counting – how will technology support research into medication adherence?: 4
COLEY, K. *see* FENG, Y.
COLLIER, P.S. *see* HAWWA, A.F.
COLLIER, P.S. *see* MUKATTASH, T.L.
COLLINS, C. *see* HYLAND, R.
COLLINS, J. *see* HAWWA, A.F.
COOPER, D. *see* NOVO, G.
CORRALL, R.J.M. *see* PARKER, D.R.
COSENTINO, M. *see* LORASCHI, A.

© 2008 The British Pharmacological Society

COSTAGLIOLA, C., CIPOLLONE, U., RINALDI, M., DELLA CORTE, M., SEMERARO, F. & ROMANO, M.R. Intravitreal bevacizumab (Avastin®) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up: 667
CREMA, F. *see* LORASCHI, A.
CREMERS, S.C. *see* WILLEMZE, A.J.

DAHAN, A. *see* ZOETHOUT, R.W.M.
DALL, M. *see* GULMEZ, S.E.
DANHOF, M. *see* MULLER, A.E.
DAR, K.A. *see* GUPTA, V.
DAVEY, K. *see* WAN, E.W-X.
DAVIDSON, D.M. *see* PEPPE, J.
DAVIDSON, J.B. *see* ROLAN, P.
DE ALMEIDA NETO, A.C. & ASLANI, P. Medicines concordance in clinical practice: 453
DE BOER, A. *see* SCHELLENS, J.H.M.
DE GIER, J.J. *see* SMINK, B.E.
DE JONGH, J. *see* MULLER, A.E.
DE JONG-VAN DEN BERG, L.T.W. *see* VEGTER, S.
DE KAM, M.L. *see* FRANSON, K.L.
DE PAUW, M. *see* SEKAR, V.J.
DE SMEDT, G. *see* SCHÖLLER-GYÜRE, M.
DE SMEDT, R.H.E., JAARSMA, T., VAN DEN BROEK, S.A.J. & HAAIJER-RUSKAMP, F.M. Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report: 327
DE SMET, M. *see* SCHWARTZ, J.I.
DE WIJKERSLOOTH, L.R.H., KOCH, B.C.P., MALINGRÉ, M.M., SMITS, P. & BARTELINK, A.K.M. Life-threatening hypokalaemia and lactate accumulation after autointoxication with Stacker 2®, a 'powerful slimming agent': 728
DE ZEEUW, D. *see* HEERSPINK, H.J.L.
DE ZEEUW, D. *see* LAMBERS HEERSPINK, H.J.
DELLA CORTE, M. *see* COSTAGLIOLA, C.
DEMPSEY, S. *see* HAWWA, A.F.
DEN HARTIGH, J. *see* WILLEMZE, A.J.
DENDLE, C. *see* HOLMES, N.E.
DERDAK, Z. *see* MIRDAMADI, H.Z.
DERRY, S. *see* STRAUBE, S.
DESBOROUGH, J. *see* HOLLAND, R.
DI GIANANTONIO, E. *see* DIAV-CITRIN, O.
DIAV-CITRIN, O., SHECHTMAN, S., WEINBAUM, D., WAJNBERG, R., AVGIL, M., DI GIANANTONIO, E., CLEMENTI, M., WEBER-SCHOENDORFER, C., SCHAEFER, C. & ORNOY, A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study: 695
DICKERMAN, R.D. *see* TACKETT, J.
DICKINS, M. *see* HYLAND, R.
DIJKHUIZEN, A. *see* SMINK, B.E.
DITERICH, I. *see* HALBSGUTH, U.
DITTRICH, C. *see* ZANDVLIET, A.S.
DIXON, R., JOB, S., OLIVER, R., TOMPSON, D., WRIGHT, J.G., MALTBY, K., LORCH, U. & TAUBEL, J. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects: 396
DOBRE, D. *see* LAMBERS HEERSPINK, H.J.
DOKI, K. *see* SUZUKI, Y.
DÖRR, P.J. *see* MULLER, A.E.
DOUGLAS, I. *see* GROSSO, A.
DRAGOMIR, A. *see* BLOUIN, J.
DRAGOMIR, A. *see* PERREAULT, S.
DUBOIS, E.A. *see* FRANSON, K.L.
DUFFULL, S.B. *see* ROOS, J.F.
DUMONT, G.J.H. *see* ZOETHOUT, R.W.M.

EARL, J.W. *see* NATH, C.E.
EDDLESTON, M. *see* EYER, P.
EDSBÄCKER, S. *see* VAN DEN BRINK, K.I.M.
EDWARDS, G. *see* MUCHOHI, S.N.
EGBERTS, A.C.G. *see* SMINK, B.E.
EICH-HÖCHLI, D. *see* HALBSGUTH, U.
ERNAWATI, D.K., STAFFORD, L. & HUGHES, J.D. Amiodarone-induced pulmonary toxicity: 82
ERNST, E. Reply to Milgrom and Moebius: 157
ERNST, E. *see* JANG, D.-J.
ERNSTOFF, M.S. *see* NEWSOME, B.W.
ETIENNE-GRIMALDI, M.-C. *see* MILANO, G.
EUM, S.Y. *see* LIMK, S.
EYER, P., EDDLESTON, M., THIERMANN, H., WOREK, F. & BUCKLEY, N.A. Are we using the right dose? – A tale of mole and gram: 451

FAHEY, T. *see* WEI, L.
FAIRWOOD, J. *see* SINGH, D.
FATTINGER, K. *see* HALBSGUTH, U.
FAZIO, G. *see* NOVO, G.
FEELY, J. *see* OKECHUKWU, I.
FENG, Y., POLLOCK, B.G., COLEY, K., MARDER, S., MILLER, D., KIRSHNER, M., ARAVAGIRI, M., SCHNEIDER, L. & BIES, R.R. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study: 629
FERNANDES, J.C. *see* BLOUIN, J.
FERNER, R.E. Post-mortem clinical pharmacology: 430
FERRO, A. *see* GOODMAN, T.
FIRENZUOLI, F. *see* LAPI, F.
FLEMING, D.H. *see* MATHEW, B.S.
FORMENTO, J.-L. *see* MILANO, G.
FOSBØL, E.L. *see* SØRENSEN, R.
FOURRIER-REGLAT, A. *see* GRÉGOIRE, F.
FRANCOUAL, M. *see* MILANO, G.
FRANSON, K.L., DUBOIS, E.A., DE KAM, M.L. & COHEN, A.F. Measuring learning from the TRC pharmacology E-Learning program: 135

GADZIK, F. *see* BABU, K.S.
GALLO, E. *see* LAPI, F.
GAMBLE, G. *see* PARKER, D.R.
GARDINER, S.J., KIRKPATRICK, C.M.J., ZHANG, M. & BEGG, E.J. Cimetidine does not appear to influence the distribution of metformin into human milk: 564
GAWARAMMANA, I. *see* KARALLEIDIE, L.
GERMANO, I. *see* PEREIRA, S.A.
GIBBONS, J.A. *see* ROLAN, P.
GISLASON, G.H. *see* SØRENSEN, R.
GOLDER, S. & LOKE, Y.K. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?: 767
GOODMAN, T., FERRO, A. & SHARMA, P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review: 222

GOODYER, L. *see* HOLLAND, R.
GORI, L. *see* LAPI, F.
GOTTESDIENER, K.M. *see* MISTRY, G.C.
GRAHAM, A. *see* WARING, W.S.
GRAY, J. *see* WARING, W.S.
GRÉGOIRE, F., PARIENTE, A., FOURRIER-REGLAT, A., HARAMBURU, F., BÉGAUD, B. & MOORE, N. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding: 142
GRIGNASCHI, N. *see* LINK, B.
GROBBEE, D.E. *see* HEERSPINK, H.J.L.
GROBBEE, D.E. *see* LAMBERS HEERSPINK, H.J.
GROSS, A.S. *see* ADKISON, K.K.
GROSS, M.I. *see* ROLAN, P.
GROSSO, A., DOUGLAS, I., HINGORANI, A., MACALLISTER, R. & SMEETH, L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions: 689
GROULS, R. *see* SCHELLENS, J.H.M.
GUARNERI, B. *see* VACCARO, M.
GUARNERI, F. *see* VACCARO, M.
GUCHELAAR, H.J. *see* SCHELLENS, J.H.M.
GULMEZ, S.E., LASSEN, A.T., AALYKKE, C., DALL, M., ANDRIES, A., ANDERSEN, B.S., HANSEN, J.M., ANDERSEN, M. & HALLAS, J. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case–control study: 294
GUMBS, C.P. *see* SCHWARTZ, J.I.
GUPTA, A., BADYAL, D.K., KHOSLA, P.P., UPPAL, B., JAISON, T.M. & CHOPRA, S. Effect of atorvastatin on hs-CRP in acute coronary syndrome: 411
GUPTA, V., RIZVI, W., DAR, K.A., BHARGAVA, R. & KUMAR, A. Haemoptysis associated with gatifloxacin in a 27 year old male asthmatic – a case report: 148
GUTTILLA, D. *see* NOVO, G.

HAAIJER-RUSKAMP, F.M. *see* DE SMEDT, R.H.E.
HABUCHI, T. *see* SATOH, S.
HALBSGUTH, U., RENTSCH, K.M., EICH-HÖCHLI, D., DITERICH, I. & FATTINGER, K. Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure: 781
HALL, S. *see* HOLLAND, R.
HALLAS, J. *see* GULMEZ, S.E.
HANSEN, J.M. *see* GULMEZ, S.E.
HARAMBURU, F. *see* GRÉGOIRE, F.
HARANGI, M. *see* MIRDAMADI, H.Z.
HARTMANN, P.E. *see* WAN, E.W-X.
HASCHKE, M. *see* LINK, B.
HAWWA, A.F., COLLIER, P.S., MILLERSHIP, J.S., MCCARTHY, A., DEMPSEY, S., CAIRNS, C. & MCELNAY, J.C. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia: 826
HAWWA, A.F., MILLERSHIP, J.S., COLLIER, P.S., VANDENBROECK, K., MCCARTHY, A., DEMPSEY, S., CAIRNS, C., COLLINS, J., RODGERS, C. & MCELNAY, J.C. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine: 517
HE, L. *see* ROLAN, P.
HEATON, A., WEBB, D.J. & MAXWELL, S.R.J. Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates: 128
HEERSPINK, H.J.L., KNOL, M.J., TIJSSEN, R.J.W., VAN LEEUWEN, T.N., GROBBEE, D.E. & DE ZEEUW, D. Is the randomized controlled drug trial in Europe lagging behind the USA?: 774
HELIN-SALMIVAARA, A.
HENNERMANN, K.-H. *see* TESCHKE, R.
HENNESSY, S., LEONARD, C.E., NEWCOMB, C., KIMMEL, S.E. & BILKER, W.B. Cisapride and ventricular arrhythmia: 375
HERMAN, G.A. *see* MISTRY, G.C.
HILLEGE, H.L. *see* LAMBERS HEERSPINK, H.J.
HINGORANI, A. *see* GROSSO, A.
HODGKINSON, M. *see* HOLMES, N.E.
HOETELMANS, R.M. *see* SEKAR, V.J.
HOETELMANS, R.M.W. *see* SCHÖLLER-GYÜRE, M.
HOFMAN B.J.A. *see* SMINK, B.E.
HOFMAN, A. *see* VAN DER HOOFT, C.S.
HOFMAN, P. *see* MILANO, G.
HOLFORD, N.H.G. *see* IIDA, S.
HOLGATE, S.T. *see* BABU, K.S.
HOLLAND, R., LOKE, Y.K., DESBOROUGH, J., WRIGHT, D., HALL, S. & GOODYER, L. Pharmacist-led medication review: response to Silcock & Petty: 576
HOLMES, N.E., HODGKINSON, M., DENDLE, C. & KORMAN, T.M. Report of oral clarithromycin desensitization: 323
HOLZGRABE, U. *see* LANDERSDORFER, C.B.
HOMMA, M. *see* SUZUKI, Y.
HORI, M. *see* ABE, T.
HOWARD, R.F. *see* STANDING, J.F.
HRENIUK, D. *see* MISTRY, G.C.
HU, Y.-Q. *see* ZHANG, Y.
HUGHES, D. Medicines concordance and game theory: 577
HUGHES, J.D. *see* ERNAWATI, D.K.
HUGTENBURG, J.G. *see* MENCKEBERG, T.T.
HUITEMA, A.D.R. *see* ZANDVLIET, A.S.
HUNT, T.L. *see* KOVARIK, J.M.
HUUPPONEN, R. *see* RUOKONIEMI, P.
HYLAND, R., DICKINS, M., COLLINS, C., JONES, H. & JONES, B. Maraviroc: *in vitro* assessment of drug–drug interaction potential: 498

IESTER, M. *see* BAGNIS, A.
IIDA, S., KINOSHITA, H. & HOLFORD, N.H.G. Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure: 352
ILETT, K.F. *see* WAN, E.W-X.
INOUE, K. *see* SATOH, S.
INOUE, T. *see* SATOH, S.
ISHITSU, T. *see* ABE, T.
ITAGAKI, F. *see* SUZUKI, Y.

JAARSMA, T. *see* DE SMEDT, R.H.E.
JAISON, T.M. *see* GUPTA, A.

JANG, D.-J., LEE, M.S., SHIN, B.-C., LEE, Y.-C. & ERNST, E. Red ginseng for treating erectile dysfunction: a systematic review: 444
JANG, I.-J. *see* KIM, J.-R.
JANG, I.-J. *see* LIMK, S.
JEON, J.-Y. *see* LIMK, S.
JEONG, D.-C. *see* YOON, J.S.
JESPERSEN, J.J. *see* BØNNELYKKE, K.
JEYASEELAN, V. *see* MATHEW, B.S.
JIANG, X.-H. *see* ZHANG, Y.
JITTIWUTIKARN, J. *see* SOMOGYI, A.A.
JLAIEL, M. *see* ROUSTIT, M.
JOB, S. *see* DIXON, R.
JOHANSEN, O.E. & WHITFIELD, R. Exenatide may aggravate moderate diabetic renal impairment: a case report: 568
JOHN, G.T. *see* MATHEW, B.S.
JOHNSON, A. *see* STANDING, J.F.
JOHNSON, K.W. *see* ROLAN, P.
JONES, B. *see* HYLAND, R.
JONES, D. *see* ROLAN, P.
JONES, H. *see* HYLAND, R.

KAGAYA, H. *see* SATOH, S.
KAKUDA, T.N. *see* SCHÖLLER-GYÜRE, M.
KALLIOKOSKI, A., NEUVONEN, M., NEUVONEN, P.J. & NIEMI, M. The effect of *SLCO1B1* polymorphism on repaglinide pharmacokinetics persists over a wide dose range: 818
KANG, D.-H. *see* KIM, J.-R.
KANG, J.H. *see* YOON, J.S.
KARALLEIDIE, L. & GAWARAMMANA, I. Traditional Herbal Medicines: a Guide to Their Safer Use: 418
KASTRISSIOS, H. *see* ROHATAGI, S.
KAUFMAN, D.M. *see* TABIBIAN, J.H.
KELMAN, C. *see* RINGLAND, C.
KHOSLA, P.P. *see* GUPTA, A.
KILDEMOES, H.W., STØVRING, H. & ANDERSEN, M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model: 885
KIM, B.-H. *see* LIMK, S.
KIM, J.-R., SEO, H.-B., CHO, J.-Y., KANG, D.-H., KIM, Y.K., BAHK, W.-M., YU, K.-S., SHIN, S.-G., KWON, J.S. & JANG, I.-J. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients: 802
KIM, J.T. *see* YOON, J.S.
KIM, J.W. *see* LIMK, S.
KIM, Y.K. *see* KIM, J.-R.
KIMMEL, S.E. *see* HENNESSY, S.
KINOSHITA, H. *see* IIDA, S.
KINZIG, M. *see* LANDERSDORFER, C.B.
KIRKPATRICK, C.M.J. *see* GARDINER, S.J.
KIRKPATRICK, C.M.J. *see* LANDERSDORFER, C.B.
KIRKPATRICK, C.M.J. *see* ROOS, J.F.
KIRSHNER, M. *see* FENG, Y.
KLAUKKA, T. *see* RUOKONIEMI, P.
KNOL, M.J. *see* Heerspink H.J.L.
KØBER, L. *see* SØRENSEN, R.
KOCH, B.C.P. *see* DE WIJKERSLOOTH, L.R.H.
KOH, Y.Y. *see* YOON, J.S.
KOHDA, Y. *see* SUZUKI, Y.
KOKWARO, G.O. *see* MUCHOHI, S.N.
KOO, S.H. *see* ADKISON, K.K.
KORKMAZ, A. Melatonin as an adjuvant therapy in patients with rheumatoid arthritis: 316
KORMAN, T.M. *see* HOLMES, N.E.
KOVARIK, J.M., SLADE, A., RIVIERE, G.-J., NEDDERMANN, D., MATON, S., HUNT, T.L. & SCHMOUDER, R.L. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects: 199
KRÄHENBÜHL, S. *see* LINK, B.
KUMAR, A. *see* GUPTA, V.
KWON, J.S. *see* KIM, J.-R.

LACOUR, J.-P. *see* MILANO, G.
LAI, S. *see* BAGNIS, A.
LALONDE, L. *see* PERREAULT, S.
LAMBERS HEERSPINK, H.J., DOBRE, D., HILLEGE, H.L., GROBBEE, D.E. & DE ZEEUW, D. Does the European Clinical Trials Directive really improve clinical trial approval time?: 546
LAMMERS, J.-W. *see* MENCKEBERG, T.T.
LAMPREIA, F. *see* PEREIRA, S.A.
LANDERSDORFER, C.B., KIRKPATRICK, C.M.J., KINZIG, M., BULITTA, J.B., HOLZGRABE, U. & SÖRGEL, F. Inhibition of flucloxacillin tubular renal secretion by piperacillin: 648
LANGLEY, S. *see* SINGH, D.
LANKESTER, A.C. *see* WILLEMZE, A.J.
LAPEYRE-MESTRE, M. *see* MOLOKHIA, M.
LAPEYRE-MESTRE, M. *see* SAILLER, L.
LAPI, F., GALLO, E., BERNASCONI, S., VIETRI, M., MENNITI-IPPOLITO, F., RASCHETTI, R., GORI, L., FIRENZUOLI, F., MUGELLI, A. & VANNACCI, A. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products: 572
LARSEN, M. *see* SOMOGYI, A.A.
LASSALLE, S. *see* MILANO, G.
LASSEN, A.T. *see* GULMEZ, S.E.
LAUNAY, F. *see* SAILLER, L.
LECCHINI, S. *see* LORASCHI, A.
LECLERCQ, P. *see* ROUSTIT, M.
LEE H.S. *see* YOON, J.S.
LEE, D.Y. *see* ADKISON, K.K.
LEE, E.J.D. *see* ADKISON, K.K.
LEE, J.S. *see* YOON, J.S.
LEE, K.Y. *see* YOON, J.S.
LEE, M.S. *see* JANG, D.-J.
LEE, Y.-C. *see* JANG, D.-J.
LEFEBVRE, E. *see* SEKAR, V.J.
LEONARD, C.E. *see* HENNESSY, S.
LI, K.-X. *see* ZHANG, Y.-T.
LI, L. *see* ADKISON, K.K.
LI, Z.-R. *see* ZHANG, Y.
LIMK, S., CHO, J.-Y., JANG, I.-J., KIM, B.-H., KIM, J.W., JEON, J.-Y., TAE, Y.-M., YI, S.J., EUM, S.Y., SHIN, S.-G. & YU, K.-S. Pharmacokinetic interaction of flecainide and paroxetine in relation to the *CYP2D6*10* allele in healthy Korean subjects: 660
LINK, B., HASCHKE, M., GRIGNASCHI, N., BODMER, M., ASCHMANN, Y.Z., WENK, M. & KRÄHENBÜHL, S. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping: 473
LIPWORTH, B.J. *see* NAIR, A.
LOKE, Y.K. *see* GOLDER, S.
LOKE, Y.K. *see* HOLLAND, R.
LORASCHI, A., MARELLI, R., CREMA, F., LECCHINI, S. & COSENTINO, M.

An unusual systemic reaction associated with topical salicylic acid in a paediatric patient: 152
LORCH, U. *see* DIXON, R.
LOU, Y. *see* ADKISON, K.K.
LUSTHOF, K.J. *see* SMINK, B.E.

MA, G. *see* ZHANG, Y.
MACALLISTER, R. *see* GROSSO, A.
MACDONALD, T.M. *see* WEI, L.
MADSEN, J.K. *see* SØRENSEN, R.
MAHMUD, A. *see* OKECHUKWU, I.
MALATINO, L.S. *see* ATTINÀ, T.M.
MALINGRÉ, M.M. *see* DE WIJKERSLOOTH, L.R.H.
MALTBY, K. *see* DIXON, R.
MANGONI, A.A. *see* BAUGHMAN, C.
MANGONI, A.A. *see* TOCHIHARA, Y.
MANT, A. *see* RINGLAND, C.
MARDER, S. *see* FENG, Y.
MARELLI, R. *see* LORASCHI, A.
MARI, M. *see* MILANO, G.
MATHEW, B.S., FLEMING, D.H., JEYASEELAN, V., CHANDY, S.J., ANNAPANDIAN, V.M., SUBBANNA, P.K. & JOHN, G.T. A limited sampling strategy for tacrolimus in renal transplant patients: 467
MATON, S. *see* KOVARIK, J.M.
MATSUSHIMA, S. *see* ASAJIMA, H.
MAXWELL, S.R.J. & WEBB, D.J. Internet pharmacy: a web of mistrust?: 196
MAXWELL, S.R.J. *see* HEATON, A.
MCCARTHY, A. *see* HAWWA, A.F.
MCELNAY, J.C. *see* HAWWA, A.F.
MCELNAY, J.C. *see* MUKATTASH, T.L.
MCFARLANE, L. *see* NAIR, A.
MCGETTIGAN, P. *see* RINGLAND, C.
MCKEIGUE, P. *see* MOLOKHIA, M.
MCLACHLAN, A.J. *see* ROOS, J.F.
MCQUAY, H.J. *see* STRAUBE, S.
MEHTA, A.A. *see* ADKISON, K.K.
MENCKEBERG, T.T., BOUVY, M.L., BRACKE, M., HUGTENBURG, J.G., LAMMERS, J.-W. & RAAIJMAKERS, J.A.M. Patients' understanding of the reasons for starting and discontinuing inhaled corticosteroids: 255
MENNITI-IPPOLITO, F. *see* LAPI, F.
MENZIES, D. *see* NAIR, A.
MERCURY, J. *see* XU, J.
MICHENOT, F. *see* SAILLER, L.
MICHIELS, N. *see* SCHWARTZ, J.I.
MILANO, G., ETIENNE-GRIMALDI, M.-C., MARI, M., LASSALLE, S., FORMENTO, J.-L., FRANCOUAL, M., LACOUR, J.-P. & HOFMAN, P. Candidate mechanisms for capecitabine-related hand–foot syndrome: 88
MILGROM, L.R. & MOEBIUS, S. Is using Nazi research to condemn homeopathy ethical or scientific?: 156
MILLER, D. *see* FENG, Y.
MILLERSHIP, J.S. *see* HAWWA, A.F.
MILLERSHIP, J.S. *see* MUKATTASH, T.L.
MINERS, J.O. *see* POLASEK, T.M.
MIRDAMADI, H.Z., SZTANEK, F., DERDAK, Z., SERES, I., HARANGI, M. & PARAGH, G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters: 366
MISTRY, G.C., BERGMAN, A.J., ZHENG, W., HRENIUK, D., ZINNY, M.A., GOTTESDIENER, K.M., WAGNER, J.A., HERMAN, G.A. & RUDDY, M. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects: 36
MITCHELL, P. *see* RINGLAND, C.
MIURA, M. *see* SATOH, S.
MOBERLY, J.B. *see* ROHATAGI, S.
MOEBIUS, S. *see* MILGROM, L.R.
MOHAMMED, Z.S., SIMI, Z.R., TARIQ, S.M. & ALI, K.R. Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate: 726
MOLOKHIA, M., PATHAK, A., LAPEYRE-MESTRE, M., CATURLA, L., MONTASTRUC, J.L. & MCKEIGUE, P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France: 386
MONTASTRUC, J.L. *see* MOLOKHIA, M.
MONTASTRUC, J.-L. *see* SAILLER, L.
MONTASTRUC, J.L. *see* TAVASSOLI, N.
MONTASTRUC-FOURNIER, J. *see* TAVASSOLI, N.
MONTEIRO, E.C. *see* PEREIRA, S.A.
MOORE, N. *see* GRÉGOIRE, F.
MOORE, R.A. *see* STRAUBE, S.
MORETTI, U. *see* VELO, G.
MORI, M. *see* NEGISHI, M.
MORIDE, Y. *see* BLOUIN, J.
MOUTON, J.W. *see* MULLER, A.E.
MUCHOHI, S.N., KOKWARO, G.O., OGUTU, B.R., EDWARDS, G., WARD, S.A. & NEWTON, C.R.J.C. Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions: 529
MUGELLI, A. *see* LAPI, F.
MUKATTASH, T.L., MILLERSHIP, J.S., COLLIER, P.S. & MCELNAY, J.C. Public awareness and views on unlicensed use of medicines in children: 838
MULLER, A.E., DÖRR, P.J., MOUTON, J.W., DE JONGH, J., OOSTVOGEL, P.M., STEEGERS, E.A.P., VOSKUYL, R.A. & DANHOF, M. The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women: 866
MURDOCH, R. *see* SINGH, D.
MUSSER, B.J. *see* SCHWARTZ, J.I.

NAIR, A., MENZIES, D., BARNES, M., BURNS, P., MCFARLANE, L. & LIPWORTH, B.J. Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler: 20
NAKAGAWA, K. *see* ABE, T.
NAKAGAWA, T. *see* ABE, T.
NATH, C.E., EARL, J.W., PATI, N., STEPHEN, K. & SHAW, P.J. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients: 50
NEDDERMANN, D. *see* KOVARIK, J.M.
NEGISHI, M., SHIMOMURA, K., PROKS, P., SHIMOMURA, Y. & MORI, M. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients: 318

NEUVONEN, M. *see* KALLIOKOSKI, A.
NEUVONEN, P.J. *see* KALLIOKOSKI, A.
NEUVONEN, P.J. *see* RUOKONIEMI, P.
NEWCOMB, C. *see* HENNESSY, S.
NEWRICK, P.G. *see* PARKER, D.R.
NEWSOME, B.W. & ERNSTOFF, M.S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?: 6
NEWTON, C.R.J.C. *see* MUCHOHI, S.N.
NIEMI, M. *see* KALLIOKOSKI, A.
NOVO, G., GUTTILLA, D., FAZIO, G., COOPER, D. & NOVO, S. The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS: 345
NOVO, S. *see* NOVO, G.
NUMAKURA, K. *see* SATOH, S.

OGUTU, B.R. *see* MUCHOHI, S.N.
OH, J.-W. *see* YOON, J.S.
OKECHUKWU, I., MAHMUD, A., BENNETT, K. & FEELY, J. Choice of first antihypertensive – are existing guidelines ignored? Response to Vegter & de Jong-van den Berg.: 561
OLIVER, J.J. *see* ATTINÀ, T.M.
OLIVER, R. *see* DIXON, R.
OOSTVOGEL, P.M. *see* MULLER, A.E.
OPATRNY, L., 'CHRIS' DELANEY, J.A. & SUISSA, S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look: 76
ORNOY, A. *see* DIAV-CITRIN, O.

PAGE-SHARP, M. *see* WAN, E.W-X.
PALTANSING, S. *see* ZOETHOUT, R.W.M.
PAPOILA, A.L. *see* PEREIRA, S.A.
PARAGH, G. *see* MIRDAMADI, H.Z.
PARIENTE, A. *see* GRÉGOIRE, F.
PARKER, D.R., BRAATVEDT, G.D., BARGIOTA, A., NEWRICK, P.G., BROWN, S., GAMBLE, G. & CORRALL, R.J.M. Glucagon is absorbed from the rectum but does not hasten recovery from hypoglycaemia in patients with type 1 diabetes: 43
PATHAK, A. *see* MOLOKHIA, M.
PATI, N. *see* NATH, C.E.
PEARSON, S.-A. *see* RINGLAND, C.
PEETERS, M. *see* SCHÖLLER-GYÜRE, M.
PEPPE, J., PORZIO, A. & DAVIDSON, D.M. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial: 102
PEREIRA, S.A., CAIXAS, U., BRANCO, T., GERMANO, I., LAMPREIA, F., PAPOILA, A.L. & MONTEIRO, E.C. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis: 551
PERREAULT, S. *see* BLOUIN, J.
PERREAULT, S., DRAGOMIR, A., BLAIS, L., BÉRARD, A., LALONDE, L. & WHITE, M. Impact of adherence to statins on chronic heart failure in primary prevention: 706
PETTY, D. *see* SILCOCK, J.
PIGEOLET, E. *see* ROLAN, P.
POLASEK, T.M. & MINERS, J.O. Macrolide–theophylline interactions: no role for the inhibition of cytochrome P4501A2: 898
POLLI, J.W. *see* ADKISON, K.K.
POLLOCK, B.G. *see* FENG, Y.
POLS, H.A.P. *see* VAN DER HOOFT, C.S.
PORZIO, A. *see* PEPPE, J.
PROKS, P. *see* NEGISHI, M.

RAAIJMAKERS, J.A.M. *see* MENCKEBERG, T.T.
RASCHETTI, R. *see* LAPI, F.
RASMUSSEN, S. *see* SØRENSEN, R.
RATABOLI, P.V. *see* AMIT, D.
RAWLINS, M.D. & SMITH, S.A. Stephen Edward Smith: 421
RENTSCH, K.M. *see* HALBSGUTH, U.
REYNOLDS, A.S. *see* TACKETT, J.
RINALDI, M. *see* COSTAGLIOLA, C.
RINGLAND, C., MANT, A., MCGETTIGAN, P., MITCHELL, P., KELMAN, C., BUCKLEY, N. & PEARSON, S.-A. Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data: 682
RITTER, J.M. Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT): 169
RITTER, J.M. Drug-induced long QT syndrome and drug development: 341
RITTER, J.M. Money makes the world go round: the pervasiveness of pharmacoeconomics: 755
RITTER, J.M. Prediction and Reverse Prediction in Therapeutics and Toxicology: 427
RITTER, J.M. Research and Education: 1
RIVIERE, G.-J. *see* KOVARIK, J.M.
RIZVI, W. *see* GUPTA, V.
RODGERS, C. *see* HAWWA, A.F.
ROHATAGI, S., KASTRISSIOS, H., SASAHARA, K., TRUITT, K., MOBERLY, J.B., WADA, R. & SALAZAR, D.E. Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain: 60
ROLAN, P., GIBBONS, J.A., HE, L., CHANG, E., JONES, D., GROSS, M.I., DAVIDSON, J.B., SANFTNER, L.M. & JOHNSON, K.W. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses: 792
ROLAN, P., SARGENTINI-MAIER, M.L., PIGEOLET, E. & STOCKIS, A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men: 71
ROMANO, M.R. *see* COSTAGLIOLA, C.
RONGEN, G.A. *see* SCHELLENS, J.H.M.
ROOS, J.F., KIRKPATRICK, C.M.J., TETT, S.E., MCLACHLAN, A.J. & DUFFULL, S.B. Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection: 455
ROSTAING, L. *see* SAILLER, L.
ROUSTIT, M., JLAIEL, M., LECLERCQ, P. & STANKE-LABESQUE, F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women: 179
ROY, K. *see* SINGH, D.
RUDDY, M. *see* MISTRY, G.C.
RUDNICKA, L. *see* TRACZEWSKI, P.
RUOKONIEMI, P., HELIN-SALMIVAARA, A., KLAUKKA, T.,

NEUVONEN, P.J. & HUUPPONEN, R. Shift of statin use towards the elderly in 1995–2005: a nation-wide register study in Finland: 405
RUSSELL, P. *see* SINGH, D.

SAILLER, L., ATTANE, C., MICHENOT, F., CANONGE, J.-M., ROSTAING, L., ARLET-SUAU, E., ARLET, P., LAUNAY, F., MONTASTRUC, J.-L. & LAPEYRE-MESTRE, M. Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey: 320
SAITO, M. *see* SATOH, S.
SAITO, N. *see* ASAJIMA, H.
SAITO, T. *see* ASAJIMA, H.
SALAZAR, D.E. *see* ROHATAGI, S.
SANDILANDS, E.A. & BATEMAN, D.N. Co-proxamol withdrawal has reduced suicide from drugs in Scotland: 290
SANFTNER, L.M. *see* ROLAN, P.
SARGENTINI-MAIER, M.L. *see* ROLAN, P.
SASAHARA, K. *see* ROHATAGI, S.
SATOH, S., KAGAYA, H., SAITO, M., INOUE, T., MIURA, M., INOUE, K., NUMAKURA, K., TSUCHIYA, N., TADA, H., SUZUKI, T. & HABUCHI, T. Lack of tacrolimus circadian pharmacokinetics and *CYP3A5* pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients: 207
SAVAGE, I. *see* STANDING, J.F.
SCHAEFER, C. *see* DIAV-CITRIN, O.
SCHELLENS, J.H.M. *see* ZANDVLIET, A.S.
SCHELLENS, J.H.M., GROULS, R., GUCHELAAR, H.J., TOUW, D.J., RONGEN, G.A., DE BOER, A. & VAN BORTEL, L.M. The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists: 146
SCHMOUDER, R.L. *see* KOVARIK, J.M.
SCHNEIDER, L. *see* FENG, Y.
SCHOEMAKER, R.C. *see* WILLEMZE, A.J.
SCHOEMAKER, R.C. *see* ZOETHOUT, R.W.M.
SCHÖLLER-GYÜRE, M., KAKUDA, T.N., DE SMEDT, G., VANAKEN, H., BOUCHE, M.-P., PEETERS, M., WOODFALL, B. & HOETELMANS, R.M.W. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers: 508
SCHOOFS, M.W.C.J. *see* VAN DER HOOFT, C.S.
SCHWARTZ, J.I., AGRAWAL, N.G.B., WEHLING, M., MUSSER, B.J., GUMBS, C.P., MICHIELS, N., DE SMET, M. & WAGNER, J.A. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib: 811
SCHWARZENBÖCK, A. *see* TESCHKE, R.
SEKAR, V.J., LEFEBVRE, E., DE PAUW, M., VANGENEUGDEN, T. & HOETELMANS, R.M. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV–healthy volunteers: 215
SEKIGUCHI, Y. *see* ASAJIMA, H.
SEMERARO, F. *see* COSTAGLIOLA, C.
SEO, H.-B. *see* KIM, J.-R.
SEO, T. *see* ABE, T.
SERES, I. *see* MIRDAMADI, H.Z.
SHAO, H. *see* ZHANG, Y.-T.
SHARMA, P. *see* GOODMAN, T.
SHAW, P.J. *see* NATH, C.E.
SHECHTMAN, S. *see* DIAV-CITRIN, O.
SHI, L.-W. *see* ZHANG, Y.-T.
SHIMOMURA, K. *see* NEGISHI, M.
SHIMOMURA, Y. *see* NEGISHI, M.
SHIN, B.-C. *see* JANG, D.-J.
SHIN, S.-G. *see* KIM, J.-R.
SHIN, S.-G. *see* LIMK, S.
SILCOCK, J. & PETTY, D. Pharmacist-led medication review: comment on Holland *et al.* 2008: 575
SIMI, Z.R. *see* MOHAMMED, Z.S.
SIMMER, K. *see* WAN, E.W-X.
SINGH, D., FAIRWOOD, J., MURDOCH, R., WEEKS, A., RUSSELL, P., ROY, K., LANGLEY, S. & WOODCOCK, A. The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics: 261
SIZOVA, L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs: 173
SJOEDSMA, A.G. Starting with serotonin: 903
SLADE, A. *see* KOVARIK, J.M.
SMEETH, L. *see* GROSSO, A.
SMINK, B.E., HOFMAN B.J.A., DIJKHUIZEN, A., LUSTHOF, K.J., DE GIER, J.J., EGBERTS, A.C.G. & UGES, D.R.A. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam: 556
SMITH, S.A. *see* RAWLINS, M.D.
SMITS, P. *see* DE WIJKERSLOOTH, L.R.H.
SOMOGYI, A.A., LARSEN, M., ABADI, R.M., JITTIWUTIKARN, J., ALI, R. & WHITE, J.M. Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics: 640
SØRENSEN, R., GISLASON, G.H., FOSBØL, E.L., RASMUSSEN, S., KØBER, L., MADSEN, J.K., TORP-PEDERSEN, C. & ABILDSTROM, S.Z. Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide study: 875
SÖRGEL, F. *see* LANDERSDORFER, C.B.
SPURLING, L. *see* BAUGHMAN, C.
STAAL-VAN DEN BREKEL, A.J. *see* VAN DEN BRINK, K.I.M.
STAFFORD, L. *see* ERNAWATI, D.K.
STANDING, J.F., HOWARD, R.F., JOHNSON, A., SAVAGE, I. & WONG, I.C.K. Population pharmacokinetics of oral diclofenac for acute pain in children: 846
STANKE-LABESQUE, F. *see* ROUSTIT, M.
STEEGERS, E.A.P. *see* MULLER, A.E.
STE-MARIE, L.-G. *see* BLOUIN, J.
STEPHEN, K. *see* NATH, C.E.
STOCKIS, A. *see* ROLAN, P.
STØVRING, H. *see* KILDEMOES, H.W.
STRAUBE, S., DERRY, S., MCQUAY, H.J. & MOORE, R.A. Enriched

enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review: 266
STURKENBOOM, M.C.J.M. *see* VAN DER HOOFT, C.S.
SU, L. *see* ZHANG, Y.
SUBBANNA, P.K. *see* MATHEW, B.S.
SUISSA, S. *see* OPATRNY, L.
SUN, C.-H. *see* ZHANG, Y.-T.
SUZUKI, T. *see* SATOH, S.
SUZUKI, Y., HOMMA, M., DOKI, K., ITAGAKI, F. & KOHDA, Y. Impact of *CYP3A5* genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects: 154
SZTANEK, F. *see* MIRDAMADI, H.Z.

TABIBIAN, J.H., TABIBIAN, N. & KAUFMAN, D.M. Late-onset celecoxib-induced combined hepatonephrotoxicity: 150
TABIBIAN, N. *see* TABIBIAN, J.H.
TACKETT, J., REYNOLDS, A.S. & DICKERMAN, R.D. Enzyme elevations with muscle injury: know what to look for!: 725
TADA, H. *see* SATOH, S.
TAE, Y.-M. *see* LIMK, S.
TARIQ, S.M. *see* MOHAMMED, Z.S.
TAUBEL, J. *see* DIXON, R.
TAVASSOLI, N., MONTASTRUC-FOURNIER, J., MONTASTRUC, J.L. Psychiatric adverse drug reactions to glucocorticoids in children and adolescents: a much higher risk with elevated doses: 566
TAYO, F. *see* YUSUFF, K.B.
TESCHKE, R., SCHWARZENBÖCK, A. & HENNERMANN, K.-H. Causality assessment in hepatotoxicity by drugs and dietary supplements: 758
TETT, S.E. *see* ROOS, J.F.
THIERMANN, H. *see* EYER, P.
THORSSON, L. *see* VAN DEN BRINK, K.I.M.
TIJSSEN, R.J.W. *see* HEERSPINK, H.J.L.
TOCHIHARA, Y., WHITING, M.J., BARBARA, J.A. & MANGONI, A.A. Effects of pre- *vs.* intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease: 717
TOMPSON, D. *see* DIXON, R.
TORP-PEDERSEN, C. *see* SØRENSEN, R.
TOUW, D.J. *see* SCHELLENS, J.H.M.
TRACZEWSKI, P. & RUDNICKA, L. Adalimumab in dermatology: 618
TRAVERSO, C.E. *see* BAGNIS, A.
TRUITT, K. *see* ROHATAGI, S.
TSUCHIYA, N. *see* SATOH, S.

UGES, D.R.A. *see* SMINK, B.E.
UPPAL, B. *see* GUPTA, A.

VACCARO, M., BARBUZZA, O., GUARNERI, F. & GUARNERI, B. Nail and periungual toxicity following capecitabine therapy: 325
VAIDYA, S.S. *see* ADKISON, K.K.
VAN BORTEL, L.M. *see* SCHELLENS, J.H.M.
VAN BRONSWIJK, P. & COHEN, A.F. The first recordings of pharmacological effects: 588
VAN BURGEL, N.D. *see* ZOETHOUT, R.W.M.
VAN DEN BRINK, K.I.M., BOORSMA, M., STAAL-VAN DEN BREKEL, A.J., EDSBÄCKER, S., WOUTERS, E.F. & THORSSON, L. Evidence of the *in vivo* esterification of budesonide in human airways: 27
VAN DEN BROEK, S.A.J. *see* DE SMEDT, R.H.E.
VAN DER HOOFT, C.S., SCHOOFS, M.W.C.J., ZIERE, G., HOFMAN, A., POLS, H.A.P., STURKENBOOM, M.C.J.M. & CH. STRICKER, B.H. Inappropriate benzodiazepine use in older adults and the risk of fracture: 276
VAN DER LINDEN, M. *see* ZOETHOUT, R.W.M.
VAN GERVEN, J.M.A. *see* ZOETHOUT, R.W.M.
VAN LEEUWEN, T.N. *see* HEERSPINK, H.J.L.
VANAKEN, H. *see* SCHÖLLER-GYÜRE, M.
VANDENBROECK, K. *see* HAWWA, A.F.
VANGENEUGDEN, T. *see* SEKAR, V.J.
VANNACCI, A. *see* LAPI, F.
VEGTER, S. & DE JONG-VAN DEN BERG, L.T.W. Choice of first antihypertensive – comparison between the Irish and Dutch setting: 313
VELO, G. & MORETTI, U. Direct-to-consumer information in Europe: the blurred margin between promotion and information: 626
VIETRI, M. *see* LAPI, F.
VOSKUYL, R.A. *see* MULLER, A.E.
VOSSEN, J.M. *see* WILLEMZE, A.J.

WADA, R. *see* ROHATAGI, S.
WAGNER, J.A. *see* MISTRY, G.C.
WAGNER, J.A. *see* SCHWARTZ, J.I.
WAJNBERG, R. *see* DIAV-CITRIN, O.
WAN, E.W-X., DAVEY, K., PAGE-SHARP, M., HARTMANN, P.E., SIMMER, K. & ILETT, K.F. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk: 283
WANDERS, J. *see* ZANDVLIET, A.S.
WANG, Z.-G. *see* ZHANG, Y.
WARD, S.A. *see* MUCHOHI, S.N.
WARING, W.S., GRAY, J. & GRAHAM, A. Predictive factors for generalized seizures after deliberate citalopram overdose: 861
WEBB, D.J. *see* ATTINÀ, T.M.
WEBB, D.J. *see* HEATON, A.
WEBB, D.J. *see* MAXWELL, S.R.J.
WEBER-SCHOENDORFER, C. *see* DIAV-CITRIN, O.
WEEKS, A. *see* SINGH, D.
WEHLING, M. *see* SCHWARTZ, J.I.
WEI, L., FAHEY, T. & MACDONALD, T.M. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour *vs.* drug effects and 10-year follow-up of outcome: 110
WEINBAUM, D. *see* DIAV-CITRIN, O.
WENK, M. *see* LINK, B.
WESTERN, A. *see* CAMPION, J.
WHITE, J.M. *see* SOMOGYI, A.A.
WHITE, M. *see* PERREAULT, S.
WHITFIELD, R. *see* JOHANSEN, O.E.
WHITING, M.J. *see* TOCHIHARA, Y.
WILLEMZE, A.J., CREMERS, S.C., SCHOEMAKER, R.C., LANKESTER, A.C., DEN HARTIGH, J., BURGGRAAF, J. & VOSSEN, J.M.

Ciclosporin kinetics in children after stem cell transplantation: 539
WONG, I.C.K. *see* STANDING, J.F.
WOODCOCK, A. *see* SINGH, D.
WOODFALL, B. *see* SCHÖLLER-GYÜRE, M.
WOREK, F. *see* EYER, P.
WOUTERS, E.F. *see* VAN DEN BRINK, K.I.M.
WRIGHT, D. *see* HOLLAND, R.
WRIGHT, J.G. *see* DIXON, R.

XU, F. *see* XU, J.
XU, J., MERCURY, J., ZHANG, Z. & XU, F. Psychological, social and behavioural factors that influence drug efficacy: a noteworthy research subject in clinical pharmacology: 901

YANG, L.-P. *see* ZHANG, Y.-T.
YI, S.J. *see* LIMK, S.
YOON, J.S., JEONG, D.-C., OH, J.-W., LEE, K.Y., LEE H.S., KOH, Y.Y., KIM, J.T., KANG, J.H. & LEE, J.S. The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection: 854
YU, K.-S. *see* KIM, J.-R.
YU, K.-S. *see* LIMK, S.
YUSUFF, K.B. & TAYO, F. Does a physician's specialty influence the recording of medication history in patients' case notes?: 308

ZANDVLIET, A.S., SCHELLENS, J.H.M., DITTRICH, C., WANDERS, J., BEIJNEN, J.H. & HUITEMA, A.D.R. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin: 485
ZHANG, M. *see* GARDINER, S.J.
ZHANG, Y., JIANG, X.-H., HU, Y.-Q., LI, Z.-R., SU, L., WANG, Z.-G. & MA, G. *MDR1* genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males: 247
ZHANG, Y.-T., YANG, L.-P., SHAO, H., LI, K.-X., SUN, C.-H. & SHI, L.-W. ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients: 240
ZHANG, Z. *see* XU, J.
ZHENG, W. *see* MISTRY, G.C.
ZIERE, G. *see* VAN DER HOOFT, C.S.
ZINNY, M.A. *see* MISTRY, G.C.
ZOETHOUT, R.W.M., VAN GERVEN, J.M.A., DUMONT, G.J.H., PALTANSING, S., VAN BURGEL, N.D., VAN DER LINDEN, M., DAHAN, A., COHEN, A.F. & SCHOEMAKER, R.C. A comparative study of two methods for attaining constant alcohol levels: 674

BJCP British Journal of Clinical Pharmacology

DOI:10.1111/j.1365-2125.2008.03338.x

SUBJECT INDEX

This index was compiled from the keywords

1′-hydroxymidazolam, 473
4-hydroxymidazolam, 473
6-mercaptopurine, 517, 826
ABCB1, 240
ABCG2 C421A, 233
absorption, 247, 781
ACE inhibitors, 345
acetylcholine, 300
acute heart failure, 352
acute lymphoblastic leukaemia, 517, 826
acute myocardial infarction, 875
acute pain, 846
adalimumab, 618
addiction, 781
adenosine, 261
adherence to medical regimen, 706
adherence, 255
administrative databases, 117
adrenal suppression, 20
adrenergic β-antagonists, 96
adverse drug reactions, 689
adverse effects, 767, 861
aged, 682
alcohol, 76, 674
alendronate, 117
amiodarone, 82
amoxicillin, 866
angina pectoris, 96
angiotensin receptor blockers, 142
angiotensin receptors blockers, 345
angle neovascularization, 667
antiepileptics, 71
antiretrovirals, 179
antithrombotic drugs, 294
anxiolytic, 594
aripiprazole, 802
arrhythmia, 386
arterial wave reflection, 717
aspirin resistance, 222
aspirin, 110, 222
asthma, 20, 96, 261
atorvastatin, 411
atrial fibrillation, 345
atropine, 199, 300
autopsy, 430
azathioprine, 517
Bayesian, 539
BCRP, 233
Beers criteria, 276
benzodiazepines, 276
bevacizumab (Avastin®), 667
bias, 767
bibliometric analysis, 774
biologic therapy, 6
biological agent, 618
biological agents, 173
biophosphonates, 594
biphasic, 594
blood concentrations, 240
bradycardia, 199
breastfeeding, 283
breath alcohol concentration, 674
bridging studies, 60
brivaracetam, 71
bronchial challenge, 261
bronchoconstriction, 96
budesonide, 27

cancer, 6
capecitabine, 88
carbamazepine, 304
carboplatin, 485
cardiac arrhythmias, 375
cardiovascular anomalies, 695
cardiovascular recurrence, 110
cardiovasculardrugs, 885
case–control study, 294
CATIE trial, 629
Centers for Medicare and Medicaid Services, 375
children, 50, 529, 539, 838, 846, 854
ciclosporin, 240, 539
circadian pharmacokinetics, 207
cisapride, 375
clamping, 674
clinical oncology, 485
clinical trial, 396
clinical trials, 838
Clopidogrel, 875
Clostridium difficile, 102
combination therapy, 173
confounding, 76, 142
congenital anomalies, 695
consent, 838
continuity of care, 255
convulsions, 529
co-proxamol, 290
covariate analysis, 866
C-reactive protein, 411
CYP2D6, 629, 660
CYP3A, 473
CYP3A5 polymorphism, 207
cytochrome P450 2D6, 802

darifenacin, 300
darunavir, 215
depth, 308
dexibuprofen, 854
diabetes mellitus, 142
diclofenac, 846
dietary supplements, 758
digitalis, 588
digoxin, 811
dihydropyrimidine dehydrogenase, 88
direct-to-consumer advertising (DTCA), 626
discontinuing treatment, 255
disease progression, 352
disease-modifying antirheumatic drugs, 173
domperidone, 283
dose–response, 594
dose-response, 861
driving forces, 885
drug effect, 588
drug interaction, 660
drug interactions, 682
drug resistance, 304
drug toxicity, 758, 861
drug utilization analysis, 885
drug utilization, 682
drug, 128
drug-blood-level, 430
Drug–drug interaction, 508
drug–drug interactions, 498
drug-induced hepatitis, 758

early rheumatoid arthritis, 173
education, 128
efavirenz concentrations, 551
elderly, 276
E-Learning, 135
endothelial function, 717

© 2008 The British Pharmacological Society

enriched enrolment, 266
epilepsy, 304
erectile dysfunction, 444, 594
esterification, 27
ethanol, 674
ethics committee, 546
etoricoxib, 811
etravirine, 508
European Clinical Trials Directive, 546

fever, 854
fingolimod, 199
flecainide, 660
flucloxacillin, 648
fluconazole, 455
fluoxetine, 695
fluticasone propionate, 20, 27
folic acid, 717
forearm blood flow, 300
forensic pharmacology, 430
fractures, 276
frequency, 308

gabapentin, 266
gastro-intesinal haemorrhage, 76
general pharmacology, 135
genetic polymorphism, 304, 802
genetics, 222, 386
genotype, 247

haemodialysis, 717
hand–foot syndrome, 88
haplotype, 247
healthy subject, 396
heart failure, 706
heart rate, 199
hepatotoxicity, 758
high-density lipoprotein, 366
history of medicine, 594
HIV mother-to-child transmission, 179
HIV, 455
hormesis, 594
hormetic, 594
human volunteers, 792
human, 27
hydroxymethylglutaryl-CoA reductase inhibitors, 405
hypoglycaemia, 43
hypokalaemia, 102

ibudilast, 792
ibuprofen, 854
immunotherapy, 6
in vitro metabolism, 498
in vivo, 27
inappropriate use, 276
incidence, 405
indisulam, 485
industry funding, 767
infant dose, 283
inflammatory bowel disease, 517
information, 626
inhaled corticosteroids, 255
initiation, 875
insufficient milk supply, 283
interaction studies, 674
interstitial lung diseases, 82
intravenous busulphan, 50
intravenous infusion, 674
iris neovascularization, 667
ivabradine, 96

jackknife, 467
J-shaped, 594

ketoconazole, 215
Ki67, 88
kymograph, 588

lactation, 283
lamotrigine,396
LC-MS/MS, 473
legislation, 290
limited sampling strategy, 467
liver function, 551
long-QT syndrome, 386
long-term adherence, 110
low-density lipoprotein, 366

maintenance stage, 207
malaria, 529
maraviroc, 498
MDR1, 247
medical education, 135
medication history, 308
memory, 594
meta-analysis, 222, 444
metabolite, 802
midazolam, 473, 529
modelling and simulation, 60
monoclonal antibodies, 6
mortality, 290
moxifloxacin, 396
multicentre clinical trial, 546
muscarinic receptors, 300
myasthenia gravis, 240
myelosuppression, 485

neovascular glaucoma, 667
nested case–control studies, 375
neuropathic pain, 266
neutropenia, 485
nitrofurantoin, 233
noncompliance, 117
NONMEM, 352, 485, 629, 826, 846
non-nucleoside reverse transcriptase inhibitor, 508
nosocomial diarrhoea, 102

OATP1B1, 818
off-label medicines, 838
off-label use, 618
omeprazole, 508
opioid dependence, 640
optimal design, 455
oral fluid, 556
organic anion transporting polypeptide, 818
osteoporosis, 117
osteoporotic fractures, 117
overdose, 290
oxazepam glucuronide, 556
oxazepam, 556

pain relief model, 60
paraoxonase, 366
paroxetine, 660, 695
patient safety, 128
percutaneous coronary intervention, 875
persistence, 875
P-glycoprotein, 247
pharmacist, 255
pharmacodynamics, 71, 352, 485, 640
pharmacoepidemiological model, 885
pharmacoepidemiology, 142, 375, 386
pharmacogenetics, 233, 517, 818, 826
pharmacogenomics, 240
pharmacokinetic interaction, 215, 648
pharmacokinetics, 50, 71, 179, 233, 352, 485, 529, 539, 556, 629, 640, 660, 781, 792, 811, 818
pharmacology, 142
pharmacovigilance, 142, 689
Phase 1, 792
phenotype, 366
phenotyping, 473
physicians' specialty, 308
piperacillin, 648
poisoning, 861
polymorphism, 233

population ageing, 885
population analysis, 485
population pharmacokinetic modelling, 866
population pharmacokinetics, 455, 802, 826, 846
post mortem, 430
postpartum period, 866
pregabalin, 266
pregnancy, 179, 695
prescribing, 128
prescriptions, 682
preterm infants, 283
prevalence, 405
prion, 594
promotion, 626
prostate, 594
protease inhibitors, 179
protein folding, 594
psoriasis, 618
psoriatic arthritis, 618
pulmonary wedge pressure, 352

QT, 396

raloxifene case-series, 689
randomized controlled trial, 774
ranitidine, 508
recording, 588
recovery from hypoglycaemia, 43
rectal glucagon, 43
recurrence, 345
red ginseng, 444
redistribution, 430
renal transplantation, 207
renin angiotensin system, 345
repaglinide, 818
reproducibility, 261
respiratory function, 96
retinal detachment, 594
reuptake inhibitors, 76
risedronate, 117
risk factors, 82
risperidone, 629
ritonavir, 215

safety and efficacy, 102
safety, 792
saliva, 473
SCN1A, 304
seizure, 594
selective serotonin, 76
serotonin toxicity, 682
Simcyp™, 498
single nucleotide polymorphism, 240
skin, 88
SLCO1B1, 818
sodium channel, 304
spacer, 20
spironolactone, 294
SSRI, 695
statin, 110, 366
statins, 405, 594, 706
stem cell transplantation, 539
stroke, 594
strontium, 689
substitution treatments, 781
sudden cardiac death, 375
symptom experience, 255
systematic review, 222, 444, 767

tacrolimus, 207, 467
Thailand, 640
therapeutic drug monitoring, 179
therapy, 6
thrombocytopenia, 485
thymidine phosphorylase, 88
tincture of opium, 640
tissue distribution, 430
TMC114, 215
TMC125, 508
tolerability, 71, 792
tolevamer, 102
torsade de pointes, 386
toxic hepatitis, 758
transporter, 233
tumor cell proliferation, 594
type 1 diabetes, 43

ucb 34714, 71
undergraduate, 128
unlicensed medicines, 838
upper gastrointestinal bleeding, 294
upper respiratory tract infection, 854
U-shaped, 594
uterine contractions, 866
utilization, 405

valacyclovir, 247
vascular endothelial growth factor, 667
veterans, 682
viral hepatitis co-infection, 551

warfarin, 76

BJCP British Journal of Clinical Pharmacology

DOI:10.1111/j.1365-2125.2008.03339.x

The Editors are grateful to the following who have reviewed for the *journal* in 2008:

L. Aagaard
L.J. Aarons
F. Abad-Santos
M.A. Ahmad Hassali
A. Ajani
B.A. Alkhalidi
K. Allegaert
L. Allen
L. Almond
V. Andersen
B.J. Anderson
P. Anderson
T.B. Andersson
H. Ando
H. Asajima
P. Aslani
I. Aziz
D. Back
J.T. Backman
M. Backonja
D. Badyal
D.G. Bailey
B.V. Bajorek
J. Baker
D.E. Baker
C. Ballard
M. Barclay
A. Bassett
D.N. Bateman
E. Begg
J. Beltrame
L. Benini
N.L. Benowitz
J.S. Bertino
R. Bies
Y. Birnbaum
P. Bitsios
R. Board
M. Boffito
S. Bonovas
C. Borghi
T. Borrie
M. Boyce
R. Bratty
R. Breckenridge
D. Breilh
R. Brundage
J. Buckingham
T. Buclin
K. Budde
P. Buffery
N. Buss
T. Butt
S. Callies
V.M. Campese
J. Camps
J.-M. Cardot
G. Carr-White
J. Chang
B.G. Charles
S. Charman
P. Chatterjee
P. Chetcuti
B. Cheung
N. Choma
I. Choonara
B. Chowbay
P.J. Chowienczyk
H. Christensen
R. Christopher
H. Chrystyn
G. Chu
J. Ciccolini
G. Cirino
S.E. Clarke
J. Coleman
A. Conforti
S. Conroy
S.A. Constable
R. Cook
M. Cooklin
C. Corrigan
A. Dahan
J.M. Dalrymple
P. Dargan
J.D. Davis
R.O. Day
F.J. De Abajo
D.P. De Alwis
D. De Argila
M.L. De Bruin
G.M. De Ferrari
L. de Jong-van den Berg
B.M. de Oliveira
P. De Smet
L. de Vane
C. de Vries
F. de Vries
S. Deakin
J.W. Dear
J.J. Deeks
J.A. Delaney
S. Derry
Z. Desta
A. Di Castelnuovo
G. Dickinson
L. Dickinson
R. Dixon
K. Donaldson
R. Donnelly
M.P. Doogue
J. Drewe
M. Drici
S. Duffull
G. Dumont
V.F. Eckardt
G. Edwards
C. Edwards
G.I. Edwards
J.-L. Elghozi
M. Elisaf
L. Endrenyi
N. Epstein
S. Evans
T. Fahey
T. Fardon
J. Feely
M. Feher
R.E. Ferner
D. Fisher
M. Fored
R. Forrest
D.J.R. Foster
A. Fourrier-Réglat
K.L. Franson
P. Friedman
F. Frueh
U. Fuhr
J. Gabrielsson
A. Galetin
A. Gammaitoni
S.J. Gardiner
M. Gawaz
G. Geisslinger
J. George
C. Ghobadi
B.E. Gidal
J. Gill
P. Gill
E. Gkaliagkousi
H. Glaeser
T.K. Goggin
J. Golding
J.A. Goldstein
T. Gori
G.G. Graham
F. Granado-Lorencio
A.G. Granas
C. Green

© 2008 The Authors
Journal compilation © 2008 The British Pharmacological Society

D.J. Greenblatt
J.P. Greving
J. Grinyo
A. Gross
M. Grube
C. Guillemette
I.D. Gukas
B.J. Gurley
R.H. Guy
J.F. Haas
C.A. Haller
B. Hamrén
F. Haramburu
J. Harenberg
E. Harrop
I. Hartz
E.A. Hasanova
M. Hauben
G. Hawksworth
P.J. Helms
N.A. Helsby
S. Heptinstall
D.A. Hesselink
N. Hewitt
C. Hiemke
A. Hilton
A. Hingorani
R. Hoetelmans
N. Holford
J. Hoskins
R. Hou Hou
B. Houston
M.A. Huestis
D.A. Hughes
A. Hughes
A.D.R. Huitema
M. Hutmacher
A. Ilan
N.M. Isa
R. Ismail
L. Iversen
G. Jackson
P.R. Jackson
P. Jadhav
R. Jalali
P. Jansen
A.G. Jardine
B. Jensen
Y. Jin
M. Joerger
S. Johannessen
T.N. Johnson
A. Johnston
A. Jones
A. Wyne Jones
D. Jones
H. Jones
R. Jones
P. Jones
V. Jullien
H. Jung
N.R. Kahan
L. Kalra
D. Kanabar
H. Kankaanranta
L. kappos
S. Kapur
J. Karlberg
S. Kasper
T. Kerbusch
S. Khan
E.D. Kharasch
R. Kharbandar
J. Kirchheiner
B. Kirkham
C.M.J. Kirkpatrick
K.T. Kivisto
I. Klebovich
C. Kloft
O. Klungel
B. Knollman
G. Kojda
J. Kolesar
G. Koren
W. Kraft
M.J. Krantz
W. Krauwinkel
N. Krishnamoorthy
W. Krzyzanski
C.R. Kumana
J. Lacey
M. Lader
J. Lampe
J.M. Lanao
A. Lanas
J.-R. Laporte
J. Larkin
M.D. Larson
K.C. Lasseter
R. Latini
A. M Layton
Y. Le Meur
S. Leask
F. Leblond
E.J.D. Lee
K.K.C. Lee
S.-Y. Lee
R. Leite
M. Lennard
W. Lenney
P. Lewis
J. Lexchin
C.J. Lin
K. Lindahl
A. Lingford-Hughes
A. LiWanPo
J. Lodge
M. Lohitnavy
J. Lotsch
R. MacAllister
R.J. MacFadyen
I. Mackenzie
M. Mackness
M. MacLeod
I.A. MacPhee
M. Magnusson
B. Malawska
A. Malizia
A.A. Mangoni
D. Mann
T. Mant
A. Mant
A. Mantel-Teeuwisse
M. Margaglione
S. Marshall
F. Martin
U. Martin
P. Matthews
I. Matthews
M. Mattson
S. Maxwell
L. Mayahi
P. McCormack
J.C. McElnay
M. McIntosh
A.J. McLachlan
J.S. McLay
B. Meibohm
I. Meineke
D. Menzies
P.A. Meredith
D.P. Mikhailidis
G. Mikus
J.O. Miners
P. Minuz
F. Mir
M.I. Mitchell
S. Miura
I.D. Montoya
O. Morgan
A.H. Morice
T.F. Munzel
M. Murray
P. Musonda
A.N. Nafziger
S. Nagasaka
I.-S. Nam
C.E. Nath

P. Neuvonen
K. Neville
S. Nicholls
G. Nicholls
V. Nielsen
M. Niemi
R. Nieuwlaat
S. Norris
T. Nunn
A. O'Brien
C. O'Callaghan
K. Ogungbenro
H. Ohtani
P. O'Kane
D. O'Mahony
G. Onder
R. Palaparthy
A. Papageorgiou
C. Paton
P. Patrignani
J. Paxton
A.G. Pedersen
R.S. Pedersen
O. Pelkonen
G. Permanand
S. Perreault
T. Planche
J. Plummer
T.M. Polasek
R. Pollok
H. Poulsen
E. Quinlivan
S.K. Quinney
V. Rabenda
J.M. Rae
I. Ragueneau-Majlessi
V. Ramchandani
S. Rattan
T. Raynor
M. Regazzi
J. Reichert
D. Reith
J. Renbarger
M. Righetti
J.M. Ritter
G. Roberto
J. Robertson
M. Robertson
P. Rolan
F. Rombout
S. Ross
L.Z. Rubenstein
J. Rudolph
C.L. Russell
J. Rymer
M. Safford
S. Salek
B.C. Sallustio
M. Schachter
T. Schalekamp
S. Schneeweiss
S. Schneider
S. Shakib
P. Sharma
G. Shenfield
N. Sherwood
J.G. Shin
S.-G. Shin
M. Shou
J. Shuster
J.S. Sidhu
C. Simard
M. Singer
D.R.J. Singer
N.K. Singh
L.A. Skoglund
J.G. Slatter
I. Smith
R. Smulders
A.A. Somogyi
A. Sparreboom
E. Spina
C.E. Staatz
J.F. Standing
A.G. Stanley
L. Steardo
A. Steinsbekk
D. Stewart
B.H. Stricker
M. Strother
V. Sung
W. Sunman
B. Szabo
S. Taddei
G. Taylor
H. Tedesco-Silva
S.E. Tett
S.H. Thomas
S. Thomas
G.A. Thompson
R.W. Thomsen
A. Thomson
M. Tobin
M. Tohkin
B. Tomlinson
D.J. Touw
D. Trenk
I.F. Troconiz
R. Troughton
J. Tsai
G. Tucker
J. Unadkat
R. Upton
Y. Uresin
M. Vaccaro
A. Vale
P. van den Bemt
T. van Gelder
J. van Gerven
A. Van Peer
T. Van Staa
B.L.G. van Wijk
A.R.H. van Zanten
J. Vella-Brincat
G. Velo
K. Venkatakrishnan
R. Venkataramanan
K.M.C. Verhamme
M.A. Veronin
P. Vestergaard
R. Vink
S. Vinker
A.A. Vinks
A.I. Vitry
O. von Richter
R. Vyas
C. Vyhlidal
J. Waite
R. Walker
K. Walsh
A. Wang
D. Wang
W.S. Waring
T. Warner
B. Weatherley
A. Webb
J. Webster
L. Wei
M. Weiss
J. Weitz
J. Westbrook
H. Whitaker
J. White
A.S. Wierzbicki
J. Wilding
P. Wilkie
I. Wilkinson
S. Wilson
L. Wise
C. Withington
F. Witter
M. Wolzt
I. Wong
D. Wood
C.E. Wood
D. Woolfson
R. Woosley
H. Yamazaki

J. Yang
R. Yates
J.H.S. You
P.J. Zed
H.-H. Zhou
Z. Zuberi

Contents

Volume 66, Number 1, July 2008

Editors' view

1 Research and Education: *J.M. Ritter*

Commentary

4 Computerised Pill Counting – how will technology support research into medication adherence?: *J.J. Coleman*

Review article

6 The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?: *B.W. Newsome & M.S. Ernstoff*

Pharmacodynamics and pharmacokinetics

20 Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler: *A. Nair, D. Menzies, M. Barnes, P. Burns, L. McFarlane & B.J. Lipworth*

27 Evidence of the *in vivo* esterification of budesonide in human airways: *K.I.M. van den Brink, M. Boorsma, A.J. Staal-van den Brekel, S. Edsbäcker, E.F. Wouters & L. Thorsson*

36 Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects: *G.C. Mistry, A.J. Bergman, W. Zheng, D. Hreniuk, M.A. Zinny, K.M. Gottesdiener, J.A. Wagner, G.A. Herman & M. Ruddy*

43 Glucagon is absorbed from the rectum but does not hasten recovery from hypoglycaemia in patients with type 1 diabetes: *D.R. Parker, G.D. Braatvedt, A. Bargiota, P.G. Newrick, S. Brown, G. Gamble & R.J.M. Corrall*

50 Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients: *C.E. Nath, J.W. Earl, N. Pati, K. Stephen & P.J. Shaw*

60 Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain: *S. Rohatagi, H. Kastrissios, K. Sasahara, K. Truitt, J.B. Moberly, R. Wada & D.E. Salazar*

71 The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men: *P. Rolan, M.L. Sargentini-Maier, E. Pigeolet & A. Stockis*

Drug safety

76 Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look: *L. Opatrny, J.A. 'Chris' Delaney & S. Suissa*

82 Amiodarone-induced pulmonary toxicity: *D.K. Ernawati, L. Stafford & J.D. Hughes*

88 Candidate mechanisms for capecitabine-related hand–foot syndrome: *G. Milano, M.-C. Etienne-Grimaldi, M. Mari, S. Lassalle, J.-L. Formento, M. Francoual, J.-P. Lacour & P. Hofman*

96 Absence of respiratory effects with ivabradine in patients with asthma: *K.S. Babu, F. Gadzik & S.T. Holgate*

102 A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial: *J. Peppe, A. Porzio & D.M. Davidson*

Therapeutics

110 Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour *vs.* drug effects and 10-year follow-up of outcome: *L. Wei, T. Fahey & T.M. MacDonald*

117 Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women: *J. Blouin, A. Dragomir, Y. Moride, L.-G. Ste-Marie, J.C. Fernandes & S. Perreault*

Education and learning

128 Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates: *A. Heaton, D.J. Webb & S.R.J. Maxwell*

135 Measuring learning from the TRC pharmacology E-Learning program: *K.L. Franson, E.A. Dubois, M.L. de Kam & A.F. Cohen*

Short report

142 A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding: *F. Grégoire, A. Pariente, A. Fourrier-Reglat, F. Haramburu, B. Bégaud & N. Moore*

Letters to the editors

146 The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists: *J.H.M. Schellens, R. Grouls, H.J. Guchelaar, D.J. Touw, G.A. Rongen, A. de Boer & L.M. Van Bortel*

148 Haemoptysis associated with gatifloxacin in a 27 year old male asthmatic – a case report: *V. Gupta, W. Rizvi, K.A. Dar, R. Bhargava & A. Kumar*

150 Late-onset celecoxib-induced combined hepatonephrotoxicity: *J.H. Tabibian, N. Tabibian & D.M. Kaufman*

152 An unusual systemic reaction associated with topical salicylic acid in a paediatric patient: *A. Loraschi, R. Marelli, F. Crema, S. Lecchini & M. Cosentino*

154 Impact of *CYP3A5* genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects: *Y. Suzuki, M. Homma, K. Doki, F. Itagaki & Y. Kohda*

156 Is using Nazi research to condemn homeopathy ethical or scientific?: *L.R. Milgrom & S. Moebius*

157 Reply to Milgrom and Moebius: *E. Ernst*

Mandarin translations section

159 Translation Section

Volume 66, Number 2, August 2008

Editors' view

169 Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT): *J.M. Ritter*

Review articles

173 Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs: *L. Sizova*

179 Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women: *M. Roustit, M. Jlaiel, P. Leclercq & F. Stanke-Labesque*

Commentary

196 Internet pharmacy: a web of mistrust?: *S.R.J. Maxwell & D.J. Webb*

Pharmacodynamics

199 The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects: *J.M. Kovarik, A. Slade, G.-J. Riviere, D. Neddermann, S. Maton, T.L. Hunt & R.L. Schmouder*

Pharmacokinetics

207 Lack of tacrolimus circadian pharmacokinetics and *CYP3A5* pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients: *S. Satoh, H. Kagaya, M. Saito, T. Inoue, M. Miura, K. Inoue, K. Numakura, N. Tsuchiya, H. Tada, T. Suzuki & T. Habuchi*

Drug interactions

215 Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV–healthy volunteers: *V.J. Sekar, E. Lefebvre, M. De Pauw, T. Vangeneugden & R.M. Hoetelmans*

Pharmacogenetics

222 Pharmacogenetics of aspirin resistance: a comprehensive systematic review: *T. Goodman, A. Ferro & P. Sharma*

233 The *ABCG2* C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects: *K.K. Adkison, S.S. Vaidya, D.Y. Lee, S.H. Koo, L. Li, A.A. Mehta, A.S. Gross, J.W. Polli, Y. Lou & E.J.D. Lee*

240 ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients: *Y.-T. Zhang, L.-P. Yang, H. Shao, K.-X. Li, C.-H. Sun & L.-W. Shi*

247 *MDR1* genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males: *Y. Zhang, X.-H. Jiang, Y.-Q. Hu, Z.-R. Li, L. Su, Z.-G. Wang & G. Ma*

Therapeutics

255 Patients' understanding of the reasons for starting and discontinuing inhaled corticosteroids: *T.T. Menckeberg, M.L. Bouvy, M. Bracke, J.G. Hugtenburg, J.-W. Lammers & J.A.M. Raaijmakers*

Methods in clinical pharmacology

261 The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics: *D. Singh, J. Fairwood, R. Murdoch, A. Weeks, P. Russell, K. Roy, S. Langley & A. Woodcock*

266 Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review: *S. Straube, S. Derry, H.J. McQuay & R.A. Moore*

Drug safety

276 Inappropriate benzodiazepine use in older adults and the risk of fracture: *C.S. van der Hooft, M.W.C.J. Schoofs, G. Ziere, A. Hofman, H.A.P. Pols, M.C.J.M. Sturkenboom & B.H. Ch. Stricker*

Drugs in pregnancy and lactation

283 Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk: *E.W-X. Wan, K. Davey, M. Page-Sharp, P.E. Hartmann, K. Simmer & K.F. Ilett*

Pharmacoepidemiology

290 Co-proxamol withdrawal has reduced suicide from drugs in Scotland: *E.A. Sandilands & D.N. Bateman*

294 Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case–control study: *S.E. Gulmez, A.T. Lassen, C. Aalykke, M. Dall, A. Andries, B.S. Andersen, J.M. Hansen, M. Andersen & J. Hallas*

Short reports

300 Contribution of the M_3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed: *T.M. Attinà, J.J. Oliver, L.S. Malatino & D.J. Webb*

304 Association between *SCN1A* polymorphism and carbamazepine-resistant epilepsy: *T. Abe, T. Seo, T. Ishitsu, T. Nakagawa, M. Hori & K. Nakagawa*

308 Does a physician's specialty influence the recording of medication history in patients' case notes?: *K.B. Yusuff & F. Tayo*

Letters to the editors

313 Choice of first antihypertensive – comparison between the Irish and Dutch setting: *S. Vegter & L.T.W. de Jong-van den Berg*

316 Melatonin as an adjuvant therapy in patients with rheumatoid arthritis: *A. Korkmaz*

318 Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients: *M. Negishi, K. Shimomura, P. Proks, Y. Shimomura & M. Mori*

320 Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey: *L. Sailler, C. Attane, F. Michenot, J.-M. Canonge, L. Rostaing, E. Arlet-Suau, P. Arlet, F. Launay, J.-L. Montastruc & M. Lapeyre-Mestre*

323 Report of oral clarithromycin desensitization: *N.E. Holmes, M. Hodgkinson, C. Dendle & T.M. Korman*

325 Nail and periungual toxicity following capecitabine therapy: *M. Vaccaro, O. Barbuzza, F. Guarneri & B. Guarneri*

327 Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report: *R.H.E. De Smedt, T. Jaarsma, S.A.J. van den Broek & F.M. Haaijer-Ruskamp*

Mandarin translations section

329 Translation Section

339 Erratum

Volume 66, Number 3, September 2008

Editors' view

341 Drug-induced long QT syndrome and drug development: *J.M. Ritter*

Review article

345 The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS: *G. Novo, D. Guttilla, G. Fazio, D. Cooper & S. Novo*

Pharmacokinetic dynamic relationships

352 Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure: *S. Iida, H. Kinoshita & N.H.G. Holford*

Pharmacogenetics

366 The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters: *H.Z. Mirdamadi, F. Sztanek, Z. Derdak, I. Seres, M. Harangi & G. Paragh*

Drug safety

375 Cisapride and ventricular arrhythmia: *S. Hennessy, C.E. Leonard, C. Newcomb, S.E. Kimmel & W.B. Bilker*

386 Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France: *M. Molokhia, A. Pathak, M. Lapeyre-Mestre, L. Caturla, J.L. Montastruc, L'Association Française des Centres Régionaux de Pharmacovigilance (CRPV) and P. McKeigue*

396 Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects: *R. Dixon, S. Job, R. Oliver, D. Tompson, J.G. Wright, K. Maltby, U. Lorch & J. Taubel*

Pharmacoepidemiology

405 Shift of statin use towards the elderly in 1995–2005: a nation-wide register study in Finland: *P. Ruokoniemi, A. Helin-Salmivaara, T. Klaukka, P.J. Neuvonen & R. Huupponen*

Short report

411 Effect of atorvastatin on hs-CRP in acute coronary syndrome: *A. Gupta, D.K. Badyal, P.P. Khosla, B. Uppal, T.M. Jaison & S. Chopra*

Letters to the editors

414 Spontaneous hyphaema in a patient on warfarin treatment: *A. Bagnis, S. Lai, M. Iester, L. Bacino & C.E. Traverso*

416 Provision of warfarin education to hospital inpatients: *C. Baughman, L. Spurling & A.A. Mangoni*

Book review

418 Traditional Herbal Medicines: a Guide to Their Safer Use: *by L. Karalleidie & I. Gawarammana; reviewed by J.M. Ritter*

Obituary

421 Stephen Edward Smith: *M.D. Rawlins & S.A. Smith*

Mandarin translations section

423 Translation Section

Volume 66, Number 4, October 2008

Editors' view

427 Prediction and Reverse Prediction in Therapeutics and Toxicology: *J.M. Ritter*

Review articles

430 Post-mortem clinical pharmacology: *R.E. Ferner*

444 Red ginseng for treating erectile dysfunction: a systematic review: *D.-J. Jang, M.S. Lee, B.-C. Shin, Y.-C. Lee & E. Ernst*

Commentaries

451 Are we using the right dose? – A tale of mole and gram: *P. Eyer, M. Eddleston, H. Thiermann, F. Worek & N.A. Buckley*

453 Medicines concordance in clinical practice: *A.C. de Almeida Neto & P. Aslani*

Pharmacokinetics

455 Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection: *J.F. Roos, C.M.J. Kirkpatrick, S.E. Tett, A.J. McLachlan & S.B. Duffull*

467 A limited sampling strategy for tacrolimus in renal transplant patients: *B.S. Mathew, D.H. Fleming, V. Jeyaseelan, S.J. Chandy, V.M. Annapandian, P.K. Subbanna & G.T. John*

473 Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping: *B. Link, M. Haschke, N. Grignaschi, M. Bodmer, Y.Z. Aschmann, M. Wenk & S. Krähenbühl*

Pharmacokinetic dynamic relationships

485 Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin: *A.S. Zandvliet, J.H.M. Schellens, C. Dittrich, J. Wanders, J.H. Beijnen & A.D.R. Huitema*

Drug interactions

498 Maraviroc: *in vitro* assessment of drug–drug interaction potential: *R. Hyland, M. Dickins, C. Collins, H. Jones & B. Jones*

508 A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers: *M. Schöller-Gyüre, T.N. Kakuda, G. De Smedt, H. Vanaken, M.-P. Bouche, M. Peeters, B. Woodfall & R.M.W. Hoetelmans*

Pharmacogenetics

517 Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine: *A.F. Hawwa, J.S. Millership, P.S. Collier, K. Vandenbroeck, A. McCarthy, S. Dempsey, C. Cairns, J. Collins, C. Rodgers & J.C. McElnay*

Pediatric clinical pharmacology

529 Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions: *S.N. Muchohi, G.O. Kokwaro, B.R. Ogutu, G. Edwards, S.A. Ward & C.R.J.C. Newton*

539 Ciclosporin kinetics in children after stem cell transplantation: *A.J. Willemze, S.C. Cremers, R.C. Schoemaker, A.C. Lankester, J. den Hartigh, J. Burggraaf & J.M. Vossen*

Methods in clinical pharmacology

546 Does the European Clinical Trials Directive really improve clinical trial approval time?: *H.J. Lambers Heerspink, D. Dobre, H.L. Hillege, D.E. Grobbee & D. de Zeeuw; for the Collaborative Study Group*

Short reports

551 Efavirenz concentrations in HIV-infected patients with and without viral hepatitis: *S.A. Pereira, U. Caixas, T. Branco, I. Germano, F. Lampreia, A.L. Papoila & E.C. Monteiro*
556 The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam: *B.E. Smink, B.J.A. Hofman, A. Dijkhuizen, K.J. Lusthof, J.J. de Gier, A.C.G. Egberts & D.R.A. Uges*

Letters to the editors

561 Choice of first antihypertensive – are existing guidelines ignored? Response to Vegter & de Jong-van den Berg.: *I. Okechukwu, A. Mahmud, K. Bennett & J. Feely*
562 Early bioavailability of inhaled salbutamol reflects lung dose in children: *K. Bønnelykke, J.J. Jespersen & H. Bisgaard*
564 Cimetidine does not appear to influence the distribution of metformin into human milk: *S.J. Gardiner, C.M.J. Kirkpatrick, M. Zhang & E.J. Begg*
566 Psychiatric adverse drug reactions to glucocorticoids in children and adolescents: a much higher risk with elevated doses: *N. Tavassoli, J. Montastruc-Fournier, J.L. Montastruc & the French Association of Regional Pharmacovigilance Centres*
568 Exenatide may aggravate moderate diabetic renal impairment: a case report: *O.E. Johansen & R. Whitfield*
570 Statins and joint pain: *J. Campion & A. Western*
572 Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products: *F. Lapi, E. Gallo, S. Bernasconi, M. Vietri, F. Menniti-Ippolito, R. Raschetti, L. Gori, F. Firenzuoli, A. Mugelli & A. Vannacci*
575 Pharmacist-led medication review: comment on Holland *et al.* 2008: *J. Silcock & D. Petty*
576 Pharmacist-led medication review: response to Silcock & Petty: *R. Holland, Y.K. Loke, J. Desborough, D. Wright, S. Hall & L. Goodyer*
577 Medicines concordance and game theory: *D. Hughes*

Mandarin translation section

578 Translation Section

Volume 66, Number 5, November 2008

Editors' view

585 Methods in clinical pharmacology – a tale of two worlds: *A.F. Cohen*

Historical commentary

588 The first recordings of pharmacological effects: *P. van Bronswijk & A.F. Cohen*

Review articles

594 Hormesis and medicine: *E.J. Calabrese*
618 Adalimumab in dermatology: *P. Traczewski & L. Rudnicka*

Commentary

626 Direct-to-consumer information in Europe: the blurred margin between promotion and information: *G. Velo & U. Moretti*

Pharmacokinetics

629 Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study: *Y. Feng, B.G. Pollock, K. Coley, S. Marder, D. Miller, M. Kirshner, M. Aravagiri, L. Schneider & R.R. Bies*

Pharmacokinetic dynamic relationships

640 Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics: *A.A. Somogyi, M. Larsen, R.M. Abadi, J. Jittiwutikarn, R. Ali & J.M. White*

Drug interactions

648 Inhibition of flucloxacillin tubular renal secretion by piperacillin: *C.B. Landersdorfer, C.M.J. Kirkpatrick, M. Kinzig, J.B. Bulitta, U. Holzgrabe & F. Sörgel*

Pharmacogenetics

660 Pharmacokinetic interaction of flecainide and paroxetine in relation to the *CYP2D6*10* allele in healthy Korean subjects: *K.S. Lim, J.-Y. Cho, I.-J. Jang, B.-H. Kim, J.W. Kim, J.-Y. Jeon, Y.-M. Tae, S.J. Yi, S.Y. Eum, S.-G. Shin & K.-S. Yu*

Therapeutics

667 Intravitreal bevacizumab (Avastin®) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up: *C. Costagliola, U. Cipollone, M. Rinaldi, M. della Corte, F. Semeraro & M.R. Romano*

Methods in clinical pharmacology

674 A comparative study of two methods for attaining constant alcohol levels: *R.W.M. Zoethout, J.M.A. van Gerven, G.J.H. Dumont, S. Paltansing, N.D. van Burgel, M. van der Linden, A. Dahan, A.F. Cohen & R.C. Schoemaker*

Drug safety

682 Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data: *C. Ringland, A. Mant, P. McGettigan, P. Mitchell, C. Kelman, N. Buckley & S.-A. Pearson*
689 Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions: *A. Grosso, I. Douglas, A. Hingorani, R. MacAllister & L. Smeeth*

Drugs in pregnancy and lactation

695 Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study: *O. Diav-Citrin, S. Shechtman, D. Weinbaum, R. Wajnberg, M. Avgil, E. Di Gianantonio, M. Clementi, C. Weber-Schoendorfer, C. Schaefer & A. Ornoy*

Pharmacoepidemiology

706 Impact of adherence to statins on chronic heart failure in primary prevention: *S. Perreault, A. Dragomir, L. Blais, A. Bérard, L. Lalonde & M. White*

Short reports

717 Effects of pre- *vs.* intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease: *Y. Tochihara, M.J. Whiting, J.A. Barbara & A.A. Mangoni*

Letters to the editors

723 Adverse drug reaction (ADR) notification drop box: an easy way to report ADRs: *D. Amit & P.V. Rataboli*

725 Enzyme elevations with muscle injury: know what to look for!: *J. Tackett, A.S. Reynolds & R.D. Dickerman*

726 Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate: *Z.S. Mohammed, Z.R. Simi, S.M. Tariq & K.R. Ali*

728 Life-threatening hypokalaemia and lactate accumulation after autointoxication with Stacker 2®, a 'powerful slimming agent': *L.R.H. de Wijkerslooth, B.C.P. Koch, M.M. Malingré, P. Smits & A.K.M. Bartelink*

732 Abstracts of the Dutch Society of Clinical Pharmacology and Biosciences Meeting of 11 April 2008

Mandarin translations section

747 Translation Section

754 Erratum

Volume 66, Number 6, December 2008

Editors' view

755 Money makes the world go round: the pervasiveness of pharmacoeconomics: *J.M. Ritter*

Review articles

758 Causality assessment in hepatotoxicity by drugs and dietary supplements: *R. Teschke, A. Schwarzenböck & K.-H. Hennermann*

767 Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?: *S. Golder & Y.K. Loke*

Research policy

774 Is the randomized controlled drug trial in Europe lagging behind the USA?: *H.J.L. Heerspink, M.J. Knol, R.J.W. Tijssen, T.N. van Leeuwen, D.E. Grobbee & D. de Zeeuw*

Pharmacokinetics

781 Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure: *U. Halbsguth, K.M. Rentsch, D. Eich-Höchli, I. Diterich & K. Fattinger*

792 Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses: *P. Rolan, J.A. Gibbons, L. He, E. Chang, D. Jones, M.I. Gross, J.B. Davidson, L.M. Sanftner & K.W. Johnson*

802 Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients: *J.-R. Kim, H.-B. Seo, J.-Y. Cho, D.-H. Kang, Y.K. Kim, W.-M. Bahk, K.-S. Yu, S.-G. Shin, J.S. Kwon & I.-J. Jang*

Drug interactions

811 Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib: *J.I. Schwartz, N.G.B. Agrawal, M. Wehling, B.J. Musser, C.P. Gumbs, N. Michiels, M. De Smet & J.A. Wagner*

Pharmacogenetics

818 The effect of *SLCO1B1* polymorphism on repaglinide pharmacokinetics persists over a wide dose range: *A. Kalliokoski, M. Neuvonen, P.J. Neuvonen & M. Niemi*

Paediatric clinical pharmacology

826 Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia: *A.F. Hawwa, P.S. Collier, J.S. Millership, A. McCarthy, S. Dempsey, C. Cairns & J.C. McElnay*

838 Public awareness and views on unlicensed use of medicines in children: *T.L. Mukattash, J.S. Millership, P.S. Collier & J.C. McElnay*

846 Population pharmacokinetics of oral diclofenac for acute pain in children: *J.F. Standing, R.F. Howard, A. Johnson, I. Savage & I.C.K. Wong*

854 The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection: *J.S. Yoon, D.-C. Jeong, J.-W. Oh, K.Y. Lee, H.S. Lee, Y.Y. Koh, J.T. Kim, J.H. Kang & J.S. Lee*

Drug safety

861 Predictive factors for generalized seizures after deliberate citalopram overdose: *W.S. Waring, J.A. Gray & A. Graham*

Drugs in pregnancy and lactation

866 The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women: *A.E. Muller, P.J. Dörr, J.W. Mouton, J. De Jongh, P.M. Oostvogel, E.A.P. Steegers, R.A. Voskuyl & M. Danhof*

Pharmacoepidemiology

875 Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide study: *R. Sørensen, G.H. Gislason, E.L. Fosbøl, S. Rasmussen, L. Køber, J.K. Madsen, C. Torp-Pedersen & S.Z. Abildstrom*

885 Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model: *H.W. Kildemoes, H. Støvring & M. Andersen*

Letters to the editors

896 QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman: *H. Asajima, Y. Sekiguchi, S. Matsushima, N. Saito & T. Saito*

898 Macrolide–theophylline interactions: no role for the inhibition of cytochrome P4501A2: *T.M. Polasek & J.O. Miners*
901 Psychological, social and behavioural factors that influence drug efficacy: a noteworthy research subject in clinical pharmacology: *J. Xu, J. Mercury, Z. Zhang & F. Xu*

Book review

903 Starting with serotonin: *A.G. Sjoedsma; reviewed by A.R. Green*

Mandarin translations section

905 Translation Section
913 Author Index
922 Subject Index
925 Reviewers for 2008